The global predictive genetic testing and consumer genomics market size was estimated at USD 3.4 billion in 2018 and is anticipated to exhibit a CAGR of 13.9% over the forecast period. The broadening horizon of predictive genetic testing as a consequence of increase in the number of partnership models among key vendors operating in the genomics industry is one of the key growth drivers. Novel partnerships enable companies to provide feasible end-to-end solutions to consumers, thereby boosting customer adoption rate.
Such partnerships among government authorities and research institutions also enhance entry prospects across the predictive genetic testing realm. Market progress is supplemented by shifting concerns of federal regulatory bodies toward the effectiveness of genetic tests. These concerns aid manufacturers and physicians in standardizing the procedure, thereby increasing the sales volume of these consumer-oriented products.
Predictive genetic testing and direct to consumer tests are majorly implemented on next-generation sequencing (NGS) platforms. Growing automation in sequencing methodologies, along with the introduction of efficient and rapid genomic sequencing procedures, is anticipated to boost advances in predictive genetic tests based on the NGS principle.
Implementation of NGS protocols for delivery of niche, fragmented point-of-care solutions across the genomics value chain drives the market. Moreover, higher penetration of outsourcing has resulted in the emergence of several companies that are engaged in providing ‘sequencing-as-a-service’ or range of sample-to-insight services.
Predictive testing is highly preferred in clinical practices and translational research for predicting the risk of diseases such as neurodegenerative diseases and cancer. This enabled it to account for the largest share in 2018. The ‘predict and prevent’ paradigm is likely to raise awareness among the population about early screening programs.
Ongoing R&D activities in genetic susceptibility testing boosted the adoption of tests for cancer susceptibility screening and appropriate prognosis by defining optimal treatment program. The presence of multigene panels for the detection of different gene mutations or variants has also accelerated the adoption of susceptibility tests, thereby boosting revenue generation.
Consumer genomics is anticipated to witness lucrative growth during the forecast period as a consequence of rapid commercialization of direct to consumer genetic tests. DTC tests allow users to gain knowledge about their ancestors, family tree, and risk of disease inheritance.
Revenue flow from prediction tests for identifying breast and ovarian cancer was observed to be highest in 2018, thus accounting for the largest share in the predictive genetic testing & consumer genomics market. Factors driving this segment include a high incidence rate of breast and ovary cancer across the globe, coupled with substantial penetration of gene susceptibility testing. As per Breastcancer.org, a nonprofit organization, around 5-10% percentage of breast and ovary cancer in the U.S. is hereditary, resulting from mutations in the BRCA1 and BRCA2 genes.
The disease indication segment is expected to show similar growth patterns in the market owing to the availability of products that cover tests for several disease categories. Predictive and pre-dispositional genetic testing aids orthopedic surgeons and physicians to understand the risk of disease development prior to the onset of symptoms, thus substantially driving this segment.
DTC (direct to consumer) settings held the largest revenue share in 2018, owing to the wider availability of direct to consumer tests at cost-effective prices and growing awareness about DTC testing techniques among patients. This aforementioned fact has resulted in increase in sales volume of DTC test kits.
The emergence of new competitors in the market lends substantial competition to large players as new entrants are adopting strategies such as the launch of gene-based services as well as post-genetic DTC counseling as an add-on service.
However, this has resulted in lower penetration of tests carried out in professional settings, as consumers are more inclined toward DTC test providers compared to physicians. With the orientation of physicians in this market, the prescription rate for these products is expected to increase considerably, thereby increasing the usage rate in professional settings.
North America dominated the market by revenue owing to the presence of several players based in the U.S. These firms hold several patents related to predictive testing and wellness genomics. Participants operating herein are undertaking several growth initiatives for maintaining their respective share and are contributing to higher revenue generation in the region. For instance, in July 2018, 23andMe Inc. entered into a collaboration with GlaxoSmithKline plc in order to discover novel targets for the elucidation of disease progression pathways and develop therapies for disease eradication.
Asia Pacific is anticipated to register the fastest CAGR as patients in countries in this region have been witnessing a surge in disposable income as well as healthcare spending. Apart from growth on the demand side, supplier potential in this region is expected to progress considerably in the coming years. Prominent participants are tapping in developing economies by providing services through distribution partners.
Some of the key participants operating in this market are 23andMe, Inc.; Myriad Genetics, Inc.; F.Hoffmann-La Roche Ltd.; Abbott Laboratories; Genesis Genetics; Agilent Technologies; Thermo Fisher Scientific, Inc.; BGI; Bio-Rad Laboratories Inc.; Illumina, Inc.; Counsyl, Inc.; and ARUP Laboratories. Several key players have implemented various agreement and collaboration models amongst themselves and with pharmaceutical manufacturers. Such collaborations aid in benefiting both the verticals in terms of advancements and consequent growth.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2025
Revenue in USD Million & CAGR from 2019 to 2025
U.S., Canada, Germany, U.K., Japan, China, Australia, India, Singapore, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you are looking for specific or additional information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global predictive genetic testing & consumer genomics market report on the basis of test type, application, setting type, and region:
Test Type Outlook (Revenue, USD Million, 2014 - 2025)
Genetic Susceptibility Test
Skin & Metabolism Genetics
Application Outlook (Revenue, USD Million, 2014 - 2025)
Predictive Genetic Testing & Consumer Genomics
Breast & Ovarian Cancer
Diabetic Screening & Monitoring
Parkinsonism / Alzheimer’s Disease
Urologic screening/ Prostate cancer screening
Orthopedic & Musculoskeletal
Other cancer screening
Setting Type Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.